


Aurobindo Pharma files ANDA for HIV generic drug

27 May 2015 | News | By BioSpectrum Bureau

Aurobindo Pharma files ANDA for HIV generic drug



Singapore: India's Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for tentative approval to the Food and Drug Administration (FDA), for the treatment of HIV.

Upon receiving tentative approval from FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President's Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

Five years back, ViiV Healthcare and Clinton Health Access Initiative (CHAI) signed an agreement to collaborate with the goal of bringing innovative formulations of medicines for the treatment and prevention of HIV/AIDS to people living with HIV in developing countries, on an affordable yet sustainable basis.

CHAI and ViiV Healthcare worked together to identify a generic partner after conducting feasibility research. Following this initial joint work, ViiV Healthcare submitted necessary documentation to the FDA providing a selective waiver letter for the five-year period of New Chemical Entity (NCE) exclusivity that would have otherwise prevented FDA review and Tentative Approval of Aurobindo Pharma's ANDA at this time.

Dr Dominique Limet, CEO, ViiV Healthcare, said, "This first ANDA for a generic dolutegravir confirms that our strong commitment to thinking and acting differently to pursue new ways to expand access to our medicines, for people living with HIV in countries where the need is most pressing, is working."

Dr David Ripin, executive vice president and chief scientific officer, CHAI, said, "UNAIDS has set global public health goals calling for 90 percent of those who are HIV-positive to know their status, 90 percent of those identified to be linked to treatment programs, and 90 percent of those in treatment to achieve undetectable viral load. To tackle these complex challenges, targeted efforts to facilitate access to HIV treatment medicines, such as dolutegravir, are needed."

Mr N Govindarajan, managing director, Aurobindo Pharma, said, "We are pleased to be part of this innovative partnership designed to accelerate access to medicines for treating HIV. Aurobindo Pharma is committed to HIV care and aims to

achieve the goals of wider access to HIV t development of this newer class of drugs and	reatment, care, and supprinced fixed-dose combinations fo	ort; seeking to address the rlow- and middle-income co	spread of HIV through untries."